Biomx INC Form 4 insider transactions

Director Susan Blum acquired options to purchase 264,000 shares of BiomX Inc. common stock on July 11, 2024.

Director Russell Greig acquired 352,000 common stock options in BiomX Inc. on July 11, 2024, according to a Form 4 filing.

Merav Bassan, Chief Development Officer of BiomX Inc., reports the acquisition of 950,000 common stock options.

Marina Wolfson, CFO of BiomX Inc., reports the acquisition of 950,000 stock options.

BiomX Inc. CEO Jonathan Eitan Solomon reports the acquisition of 3,805,000 stock options with a vesting schedule over four years.

Director Jonathan Leff reports acquisition of BiomX Inc. options, but disclaims beneficial ownership.

Director Jesse Goodman reports acquisition of 264,000 stock options in BiomX Inc.

Director Gregory Louis Merril acquired options to purchase 264,000 shares of BiomX Inc. common stock.

Director Eddie Williams reports acquisition of stock options in BiomX Inc.

Assaf Oron, Chief Business Officer of BiomX Inc., reports the acquisition of stock options.

Director Alan Charles Moses reports acquisition of options to purchase 176,000 shares of BiomX Inc. common stock.

Deerfield entities, including funds and management companies, acquired warrants to purchase BiomX Inc. common stock following stockholder approval related to the Adaptive Phage Therapeutics, Inc. merger.

OrbiMed Israel Partners Limited Partnership exercised pre-funded warrants to purchase BiomX Inc. common stock, resulting in the acquisition of shares and a subsequent disgorgement of profits to the issuer.

The Cystic Fibrosis Foundation reports acquiring and disposing of BiomX Inc. common stock and warrants, impacting their beneficial ownership.

James E. Flynn and related Deerfield entities report changes in beneficial ownership of BiomX Inc. securities following the merger with Adaptive Phage Therapeutics, including acquisitions of common stock and preferred stock.

OrbiMed Israel BioFund GP Limited Partnership and related entities acquired Series X Preferred Stock and warrants in BiomX Inc. via a private placement, convertible into common stock subject to certain ownership limitations.